At the current SP AML will most certainly move the needle. Bisantrene's potential in AML has not gone away and remains an opportunity that most ASX biotechs would kill to have.
The only reason that AML has moved down the list of commercial focus is because of the discovery of CPACS. We could have ignored CPACS and just concentrated on AML, but would anyone here have been happy with this?
CPACS was a discovery made by RAC in 2021 and is a massive opportunity, but it requires RC220. RC220 took time to develop and manufacture, but this is now complete.
In a perfect world RAC might have been able to advance CPACS slight faster, but not by much. As shareholders we have been pretty lucky that the team at RAC has remained focused on what needed to be done.
RAC - Charts & Price Action, page-21899
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.47 |
Change
0.030(2.08%) |
Mkt cap ! $254.7M | |||
| Open | High | Low | Value | Volume |
| $1.46 | $1.50 | $1.46 | $61.86K | 41.83K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2599 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.48 | 600 | 1 |
View Market Depth
| Last trade - 10.55am 12/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |